scholarly article | Q13442814 |
P356 | DOI | 10.3109/10428194.2011.623258 |
P698 | PubMed publication ID | 21919823 |
P50 | author | Luca Baldini | Q39052059 |
Agostino Cortelezzi | Q56461136 | ||
Antonino Neri | Q56850455 | ||
Giuseppe Gritti | Q57078362 | ||
Gianluigi Reda | Q59647804 | ||
Stefano Molica | Q59660152 | ||
Francesco Maura | Q92130305 | ||
P2093 | author name string | Alfonso Piciocchi | |
P433 | issue | 3 | |
P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
P304 | page(s) | 424-429 | |
P577 | publication date | 2012-01-05 | |
P1433 | published in | Leukemia & Lymphoma | Q6534493 |
P1476 | title | Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia | |
P478 | volume | 53 |
Q36892621 | A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma |
Q36768605 | Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use |
Q27022373 | New antibody approaches to lymphoma therapy |
Q37147789 | New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia |
Q36300303 | Therapeutic advancement of chronic lymphocytic leukemia |